GlassScriptPhysician profile
Alexander D Toloff
NPI 1235710765
$1,014.83
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $388 · 2023: $323 · 2024: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $501.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $131.25 | 2022 | |
| Gilead Sciences, INC. | $116.56 | 2023 | Epclusa |
| Baxter Healthcare | $103.08 | 2021 | |
| Nestle Healthcare Nutrition INC. | $100.99 | 2022 | |
| Neurelis, INC. | $94.98 | 2023 | Valtoco |
| Bayer Healthcare Pharmaceuticals INC. | $80.72 | 2022 | |
| Amgen INC. | $66.12 | 2022-2024 | Krystexxa |
| Lilly USA, LLC | $65.68 | 2022-2024 | Mounjaro |
| Abiomed | $58.17 | 2024 | Impella |
| Merck Sharp & Dohme LLC | $47.52 | 2021-2023 | Gardasil 9, M-M-R II, Vaxneuvance |
| Axsome Therapeutics, INC. | $45.36 | 2023 | Auvelity |
| Myriad Women'S Health, INC. | $41.15 | 2023 | Myrisk |
| Otsuka America Pharmaceutical, INC. | $26.84 | 2024 | Rexulti |
| Seqirus USA INC | $19.28 | 2022 | |
| Abbvie INC. | $17.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Toloff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.